secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001576280-24-000260
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q3 revenue $191.5M (+34% YoY); raises FY 2024 revenue guidance to $720-725M
--------------------------------------------------------------------------------

- Revenue $191.5M (+34% YoY); GAAP net loss $107.8M ($0.88/shr), Non-GAAP net loss $55.0M ($0.45/shr).
- Clinical test volume 53,100 (+21%), biopharma 10,500 (+40%); Guardant360 ASP >$3,000.
- Full-year 2024 revenue guidance raised to $720-725M (prior $690-700M), growth 28-29%.
- Free cash flow guidance improved to $(265)-$(275)M, improvement of $70-80M vs 2023.
- Shield IVD launched; received Medicare pricing of $920; CMS removed cost-sharing for follow-on colonoscopy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628024000260/0001576280-24-000260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628024000260/gh-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001576280-24-000260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer